Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease

被引:101
作者
Gunaratnam, NT
Jessup, TP
Inadomi, J
Lascewski, DP
机构
[1] St Joseph Mercy Hosp, Div Gastroenterol, Dept Internal Med, Ypsilanti, MI 48197 USA
[2] Univ Massachusetts, Div Gastroenterol, Dept Med, Worcester, MA USA
[3] Univ Michigan, Div Gastroenterol, Dept Med, Ann Arbor, MI USA
[4] St Joseph Mercy Hosp, Dept Clin Res, Ann Arbor, MI USA
关键词
D O I
10.1111/j.1365-2036.2006.02911.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Proton pump inhibitors are the most potent drug treatment for gastro-oesophageal reflux disease. Premeal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy. To determine the prevalence of sub-optimal proton pump inhibitor dosing in a community-based gastro-oesophageal reflux disease population. One hundred patients on proton pump inhibitors referred for persistent gastro-oesophageal reflux disease symptoms were questioned about their proton pump inhibitor dosing habits and classified as optimal or sub-optimal dosers. Optimal dosers took proton pump inhibitors with or up to 60 min before meals. Sub-optimal dosers took proton pump inhibitors > 60 min before meals, after meals, as needed, or at bedtime. Forty-six percent dosed optimally. Fifty-four percent dosed sub-optimally with 21 of 54 (39%) dosing > 60 min before meals, 16 (30%) after meals, 15 (28%) at bedtime and two (4%) as needed. Only 6% of the subjects on once-daily proton pump inhibitor regimens and 33% of subjects taking proton pump inhibitors two- to three times daily dosed in a manner that maximized acid suppression (15-30 min before a meal). In this study, 54% of patients dosed proton pump inhibitors sub-optimally and only 12% dosed in a manner that maximized acid suppression. As sub-optimal proton pump inhibitor dose timing can limit efficacy, patients with refractory symptoms should be asked about dose timing to avoid inappropriate and costly dose escalations.
引用
收藏
页码:1473 / 1477
页数:5
相关论文
共 16 条
[1]   Time trends in cost of caring for people with gastroesophageal reflux disease [J].
Bloom, BS ;
Jayadevappa, R ;
Wahl, P ;
Cacciamanni, J .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (08) :S64-S69
[2]   The epidemiology of gastroesophageal reflux disease: What we know and what we need to know [J].
Eisen, G .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (08) :S16-S18
[3]   Management of patients with symptomatic gastroesophageal reflux disease: A primary care perspective [J].
Fendrick, AM .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (08) :S29-S33
[4]  
Frank L, 2000, DIGEST DIS SCI, V45, P809, DOI 10.1023/A:1005468332122
[5]  
*GALL ORG NAT SURV, 1998, HEARTB AM
[6]  
Greenberger N J, 1998, Ann Intern Med, V129, P309
[7]   Medical therapy - Management of the refractory patient [J].
Hatlebakk, JG ;
Katz, PO ;
Castell, DO .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) :847-+
[8]   Proton pump inhibitors: better acid suppression when taken before a meal than without a meal [J].
Hatlebakk, JG ;
Katz, PO ;
Camacho-Lobato, L ;
Castell, DO .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1267-1272
[9]  
Johanson John F., 2000, American Journal of Medicine, V108, p99S
[10]   Lessons learned from intragastric pH monitoring [J].
Katz, PO .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 33 (02) :107-113